Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
238
Total raised
£3.1B
disclosed amounts
This month
£7.8M
raised so far
The Liverpool university spinout raised the capital to drive commercialisation and platform development in materials discovery.
"Materials innovation underpins progress across multiple sectors from energy to manufacturing and electronics. Matter Machine brings together exceptional scientific expertise, unique technology capabilities and a highly scalable commercial opportunity"
Most rounds here started life as a press release.
Winfred reads them overnight, pulls out the facts, checks them against Companies House and files them. It was built by C8VA, who do the same kind of work for other businesses: turning messy, unstructured material into something you can search, count and rely on.
The funding round was led by Odyssey Ventures to accelerate commercialisation and expand US operations.
"The main obstacle holding back neurotechnology today is not a lack of ideas, but hardware. MintNeuro is addressing this gap with a platform on which the entire industry can build. We were convinced to invest by its strong technology team, working chips and first long-term commercial contract"
The funding round was backed by the British Business Bank via The FSE Group to support international expansion and team growth.
"We’ve developed a solution that not only helps healthcare providers reduce their environmental impact but, importantly, our innovative technology has the potential to significantly increase the safety of clinical staff by reducing work-based exposure to the vented gas. We’re delighted to be working with The FSE Group and the South West Investment Fund as we continue to scale the business from our Devon headquarters."
HERmesa led the pre-seed round, which includes backing from multiple institutional investors and Innovate UK grants.
"When only a small minority can deliver best practice, the problem isn’t effort. It’s design. I brought what I was seeing in practice, and I brought the evidence that already existed but simply wasn’t being used consistently. Peripear exists because the standard of care couldn’t possibly be the best we could do,"
Molten Ventures led the Series B round to support the creation of an artificial intelligence imaging lab.
"There was an area to go and help these pharma companies do better clinical trials, and so that’s how the company started"
